Capricor Therapeutics (CAPR) EBITDA Margin (2011 - 2024)
Capricor Therapeutics (CAPR) recorded quarterly EBITDA Margin of 55.49% in Q4 2024, up 90.04% quarter-over-quarter from 557.12% in Q3 2024, and down 5020.0% on a YoY basis from 1.13% in Q1 2024.
Capricor Therapeutics (CAPR) EBITDA Margin (2011 - 2024) Analysis & Trends
Capricor Therapeutics' EBITDA Margin history runs 14 years deep, the most recent figure standing at 55.49% for Q4 2024.
- In Q4 2024, EBITDA Margin fell 5020.0% year-over-year to 55.49%; the TTM figure through Sep 2025 stood at 729.31% (down 60869.0% YoY), while the FY2024 annual figure was 178.16%, down 9015.0% from the prior year.
- EBITDA Margin was 55.49% for Q4 2024 at Capricor Therapeutics, up from 557.12% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 5.29% in Q4 2023 to a low of 23127.56% in Q3 2020.
- Historically, EBITDA Margin has averaged 3522.29% across 5 years, with a median of 476.48% in 2024.
- The sharpest annual moves came in 2020 and 2021: EBITDA Margin sank 2199671 bps in 2020, then jumped 469245 bps in 2021.
- A 5-year view of EBITDA Margin shows it stood at 7262.67% in 2020, then soared by 68 bps to 2326.65% in 2021, then surged by 65 bps to 804.65% in 2022, then soared by 99 bps to 5.29% in 2023, then tumbled by 949 bps to 55.49% in 2024.
- The last three EBITDA Margin figures came in at 55.49% (Q4 2024), 557.12% (Q3 2024), and 282.01% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Capricor Therapeutics | 1.53 Bn | 1.26 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -55.49% |
| Sep 30, 2024 | -557.12% |
| Jun 30, 2024 | -282.01% |
| Mar 31, 2024 | -97.22% |
| Dec 31, 2023 | -5.29% |
| Sep 30, 2023 | -105.08% |
| Jun 30, 2023 | -185.88% |
| Mar 31, 2023 | -261.16% |
| Dec 31, 2022 | -804.65% |
| Sep 30, 2022 | -395.84% |
| Jun 30, 2021 | -2,326.65% |
| Mar 31, 2021 | -12,740.10% |
| Dec 31, 2020 | -7,262.67% |
| Sep 30, 2020 | -23,127.56% |
| Jun 30, 2020 | -7,019.09% |
| Mar 31, 2020 | -1,130.90% |
| Dec 31, 2019 | -661.94% |
| Sep 30, 2019 | -1,130.84% |
| Jun 30, 2019 | -498.71% |
| Mar 31, 2019 | -1,084.58% |